<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03545126</url>
  </required_header>
  <id_info>
    <org_study_id>201703052</org_study_id>
    <nct_id>NCT03545126</nct_id>
  </id_info>
  <brief_title>Human CNS Tau Kinetics in Tauopathies</brief_title>
  <acronym>TANGLES</acronym>
  <official_title>Human CNS Tau Kinetics in Tauopathies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association of Frontotemporal Degeneration</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tau Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to characterize tau kinetics and tau aggregation in the human CNS
      and to test the hypothesis that tau kinetics are altered (i.e. increased production,
      decreased clearance, and increased aggregation rate) in tauopathies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Tauopathies are neurodegenerative diseases with tau pathology. These tauopathies are the most
      common pathology in neurodegenerative diseases, and they are reaching epidemic proportions.
      The rates of tau kinetics are central to understanding normal and abnormal processing and
      production and clearance of tau kinetics in humans to help understand the causes of tauopathy
      and evaluate tau-targeted therapeutics.

      This study will utilize the Stable Isotope Labeling Kinetics (SILK) method to elucidate tau
      kinetics in vivo in the human central nervous system (CNS) and its alteration in tauopathies.
      A total of ~34 participants from 3 different neurodegenerative diseases: Frontotemporal
      Dementia (FTD), Corticobasal Degeneration (CBD), and Progressive Supranuclear Palsy (PSP),
      will be invited to enroll in the study.

      Participants will be labeled with stable isotopes via 16hr intravenous infusion and CSF
      samples collected during subsequent lumbar puncture visits over ~120 days. CSF will be
      analyzed over time for the quantitation of labeled tau.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 21, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tau Fractional Turnover Rate (FTR)</measure>
    <time_frame>6 months</time_frame>
    <description>Calculated by using CSF tau labeling and plasma free leucine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CSF Tau Absolute Concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Measured using labeled and unlabeled tau protein isoforms that will be immunoprecipitated and analyzed by mass spectrometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tau Production Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Measured by FTR multiplied by CSF tau concentration.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Progressive Supranuclear Palsy (PSP)</condition>
  <condition>Corticobasal Degeneration (CBD)</condition>
  <condition>Frontotemporal Dementia (FTD MAPT Mutation)</condition>
  <arm_group>
    <arm_group_label>Progressive Supranuclear Palsy (PSP)</arm_group_label>
    <description>N=12 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticobasal Degeneration (CBD)</arm_group_label>
    <description>N=8 Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal Dementia: MAPT</arm_group_label>
    <description>N=12 Family members with or at-risk of tau mutations (e.g. P301L) Age: 18 and older Recruited participants will be given 13C6 Leucine through intravenous infusion (4mg/kg/hr for 16hrs), and CSF will be collected five times over 120 days (on approximately days 1-4, 5-10, 11-20, 21-60 and 61-120) after labeling.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>13C6 Leucine</intervention_name>
    <description>Recruited participants will be given 13C6-labeled leucine through intravenous infusion (4mg/kg/hr for 16hrs)</description>
    <arm_group_label>Corticobasal Degeneration (CBD)</arm_group_label>
    <arm_group_label>Frontotemporal Dementia: MAPT</arm_group_label>
    <arm_group_label>Progressive Supranuclear Palsy (PSP)</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Progressive Supranuclear Palsy (PSP): N=12

        Corticobasal Degeneration (CBD): N=8

        Frontotemporal Dementia (FTD): MAPT: Family members with or at-risk of tau mutations (e.g.
        P301L) N=12
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with PSP, CBD, or FTD MAPT

        Exclusion Criteria:

          -  Clotting disorder

          -  Active anticoagulation therapy

          -  Active infection

          -  Meningitis

          -  Recent syncope

          -  Current experimental treatment targeting Aβ or medications thought to influence Aβ
             production or clearance rates (benzodiazepines, muscarinic agents, or anti-epileptics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Randall Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University in Saint Louis Medical School</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nupur Ghoshal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University in Saint Louis Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Melissa M Sullivan</last_name>
    <phone>314-747-4857</phone>
    <email>m.sullivan@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Melody Li, MS, OTR/L</last_name>
    <phone>314-273-6062</phone>
    <email>slia@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University in St. Louis School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa M Sullivan</last_name>
      <phone>314-747-4857</phone>
      <email>m.sullivan@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Melody Li, MS, OTR/L</last_name>
      <phone>314-273-6062</phone>
      <email>slia@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Randall J Bateman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2018</study_first_posted>
  <last_update_submitted>September 23, 2019</last_update_submitted>
  <last_update_submitted_qc>September 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tauopathies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Supranuclear Palsy, Progressive</mesh_term>
    <mesh_term>Frontotemporal Dementia</mesh_term>
    <mesh_term>Aphasia, Primary Progressive</mesh_term>
    <mesh_term>Pick Disease of the Brain</mesh_term>
    <mesh_term>Tauopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided at this time.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

